Beijing Lairuisheng Pharmaceutical Technology

Beijing Lairuisheng Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the discovery and development of innovative small molecule drugs. The company primarily focuses on autoimmune diseases and inflammatory conditions, with a core expertise in developing selective kinase inhibitors. Its lead candidates include LRS007, a selective JAK1 inhibitor, and LRS008, a TYK2 inhibitor, both of which are being evaluated for various dermatological and rheumatological indications. Lairuisheng aims to provide high-quality, affordable therapeutic solutions for patients with chronic inflammatory diseases through its internal R&D capabilities.